CTRI/2016/12/007557已完成3 期
Multicenter, Double-Blind, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of MYL-1402O Compared With Avastin®, in the First-line Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer
Mylan GmbH0 个研究点目标入组 191 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 191
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Has demonstrated the ability to understand verbal and/or written instructions, to provide written informed consent, and is capable and agreeable to comply with protocol requirements.
- •2.Male or female at least 18 years of age at the time of signing an informed consent form (ICF).
- •3.Has a documented imaging diagnosis of Stage IV unresectable, recurrent or metastatic nsNSCLC.
- •4.Has measurable disease with at least 1 measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
- •5.Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale.
- •6.Has at least 6 months of expected survival.
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Study to assess the efficacy and safety of MYL-1402O Compared With the drug Avastin, in patients with lung cancer.Stage IV unresectable, recurrent or metastaticnon-squamous non-small cell lung cancer (nsNSCLC)MedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864EUCTR2015-005141-32-HRMylan GmbH640
进行中（未招募）
1 期
Study to assess the efficacy and safety of MYL-1402O Compared With the drug Avastin, in patients with lung cancer.EUCTR2015-005141-32-ITMYLAN GMBH478
进行中（未招募）
1 期
Study to assess the efficacy and safety of MYL-1402O Compared With the drug Avastin, in patients with lung cancer.Stage IV unresectable, recurrent or metastaticnon-squamous non-small cell lung cancer (nsNSCLC)MedDRA version: 19.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864EUCTR2015-005141-32-HUMylan GmbH478
进行中（未招募）
1 期
Study to assess the efficacy and safety of MYL-1402O Compared With the drug Avastin, in patients with lung cancer.EUCTR2015-005141-32-BGMylan GmbH640
进行中（未招募）
1 期
Study to assess the efficacy and safety of MYL-1402O Compared With the drug Avastin, in patients with lung cancer.Stage IV unresectable, recurrent or metastaticnon-squamous non-small cell lung cancer (nsNSCLC)MedDRA version: 19.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864EUCTR2015-005141-32-ESMylan GmbH478